{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:24:10Z","timestamp":1784042650388,"version":"3.55.0"},"reference-count":27,"publisher":"BMJ","issue":"7","funder":[{"name":"Takeda Europe Ltd. provided funding to PHMR, Ltd. to acquire data and undertake the analyses."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,6,21]]},"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the UK practice patterns in treating newly diagnosed hypertension and to determine whether subgroups of high-risk patients are more or less likely to follow particular therapeutic protocols and to reach blood pressure goals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>This study examined adults in The Health Improvement Network (THIN) UK general practice medical records database who were initiated on medication for hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>48\u2009131 patients with essential hypertension diagnosed between 2008 and 2010 who were registered with a participating practice for a minimum of 13 months prior to, and 6 months following, initiation of therapy. We excluded patients with gestational hypertension or secondary hypertension. Patients were classified into risk groups based on blood pressure readings and comorbid conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Odds of receiving single versus fixed or free-drug combination therapy and odds of achieving blood pressure control were assessed using multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The vast majority of patients (95.8%) were initiated on single drug therapy. Patients with high cardiovascular risk (patients with grade 2\u20133 hypertension or those with high normal\/grade 1 hypertension plus at least one cardiovascular condition pretreatment) had a statistically significant benefit of starting immediately on combination therapy when blood pressure control was the desired goal (OR: 1.23; 95%\u2009CI: 1.06 to 1.42) but, surprisingly, were less likely than patients with no risk factors to receive combination therapy (OR: 0.53; 95%\u2009CI: 0.47 to 0.59).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that combination therapy may be indicated for patients with high cardiovascular risk, who accounted for 60.6% of our study population. The National Institute for Health and Care Excellence guideline CG34 of 2006 (in effect during the study period) recommended starting with single drug class therapy for most patients, and this advice does seem to have been followed even in cases where a more aggressive approach might have been considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-015527","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T20:10:21Z","timestamp":1501359021000},"page":"e015527","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Relationship between initial therapy and blood pressure control for high-risk hypertension patients in the UK: a retrospective cohort study from the THIN general practice database"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-6034","authenticated-orcid":false,"given":"Sharada","family":"Weir","sequence":"first","affiliation":[{"name":"Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada"},{"name":"PHMR Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Juhasz","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Takeda Development Centre Europe Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Puelles","sequence":"additional","affiliation":[{"name":"Takeda Development Centre Europe Limited, Global Outcomes Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis S","family":"Tierney","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"2025121515254114000_7.7.e015527.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17741-1"},{"key":"2025121515254114000_7.7.e015527.2","unstructured":"Forbes C , Lang S , Harker J , et al . The epidemiology of hypertension: a literature and systematic review. York, UK: Kleijnen Systematic Reviews Ltd, 2010."},{"key":"2025121515254114000_7.7.e015527.3","unstructured":"World Health Organization (WHO). World Health Statistics 2012. Geneva, Switzerland: WHO Press, 2012. http:\/\/www.who.int\/gho\/publications\/world_health_statistics\/EN_WHS2012_Full.pdf (accessed 9 Dec 2016)."},{"key":"2025121515254114000_7.7.e015527.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00434.x"},{"key":"2025121515254114000_7.7.e015527.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5288.740"},{"key":"2025121515254114000_7.7.e015527.6","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-011-0053-1"},{"key":"2025121515254114000_7.7.e015527.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.165"},{"key":"2025121515254114000_7.7.e015527.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7440.634"},{"key":"2025121515254114000_7.7.e015527.9","unstructured":"National Institute for Health and Clinical Excellence: CG34: Hypertension: NICE\u00a0clinical guidelines. 1-6-2006 London, UK National Institute for Health and Clinical Excellence 2006 http:\/\/www.salforddiabetescare.co.uk\/admin\/resources\/uploaded\/NICE%20guidance%20on%20hypertension208.pdf (accessed 15 Apr 2017)."},{"key":"2025121515254114000_7.7.e015527.10","unstructured":"National Institute for Health and Clinical Excellence. CG127: Hypertension:Clinical management of primary hypertension in adults. 24-8-2011. London, UK: National Institute for Health and Clinical Excellence, 2011. https:\/\/www.nice.org.uk\/guidance\/cg127 (accessed 15 Apr 2017)."},{"key":"2025121515254114000_7.7.e015527.11","first-page":"1281","article-title":"ESH\/ESC guidelines for the management of arterial hypertension","volume":"31","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"2025121515254114000_7.7.e015527.12","unstructured":"Health IMS. Data: statistics. 2015. http:\/\/www.epic-uk.org\/our-data\/statistics.shtml (accessed 9 Dec 2016)."},{"key":"2025121515254114000_7.7.e015527.13","unstructured":"Health IMS. Cegedim Strategic Data:\u00a0Data Content. 2015. http:\/\/www.epic-uk.org\/our-data\/data-content.shtml (accessed 9 Dec 2016)."},{"key":"2025121515254114000_7.7.e015527.14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1335"},{"key":"2025121515254114000_7.7.e015527.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d108"},{"key":"2025121515254114000_7.7.e015527.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03072.x"},{"key":"2025121515254114000_7.7.e015527.17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1002312"},{"key":"2025121515254114000_7.7.e015527.18","unstructured":"Health IMS. Cegedim Strategic Data: ethics. 2015. http:\/\/www.epic-uk.org\/our-data\/ethics.shtml (accessed 9 Dec 2016)."},{"key":"2025121515254114000_7.7.e015527.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2025121515254114000_7.7.e015527.20","unstructured":"National Health Service, Health and Social Care Information Centre. Quality and outcomes Framework Achievement Data 2008\/09. 2013. http:\/\/content.digital.nhs.uk\/catalogue\/PUB04033\/qof-eng-08-09-bull-rep.pdf (accessed 17 Apr 2017)."},{"key":"2025121515254114000_7.7.e015527.21","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000275267.64078.B0"},{"key":"2025121515254114000_7.7.e015527.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"2025121515254114000_7.7.e015527.23","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328333146d"},{"key":"2025121515254114000_7.7.e015527.24","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2005.037457"},{"key":"2025121515254114000_7.7.e015527.25","unstructured":"National Institute for Health and Clinical Excellence. NICE Pathways: Managing\u00a0Blood Pressure in Type 2 Diabetes. London, UK: National Institute for Health and Care Excellence, 2013. https:\/\/www.nice.org.uk\/guidance\/ng28 (accessed 15 Apr 2017)."},{"key":"2025121515254114000_7.7.e015527.26","unstructured":"National Institute for Health and Clinical Excellence. NICE Pathways: possible complications of chronic kidney disease. London, UK: National Institute for Health and Care Excellence, 2013. https:\/\/www.nice.org.uk\/guidance\/cg182 (accessed 15 Apr 2017)."},{"key":"2025121515254114000_7.7.e015527.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2350"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-015527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T23:25:51Z","timestamp":1765841151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-015527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,28]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1136\/bmjopen-2016-015527"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-015527","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}